For individuals with schizophrenia and insomnia, can melatonin and CBT improve sleep, symptoms, functioning and cognitive functions

The University of Western Australia0 个研究点目标入组 13 人开始时间: 2013年8月30日最近更新: 2021年2月22日

适应症

试验速览

暂无简介。

•1. Aged 25 to 50 years.
•2. A diagnosis of schizophrenia or schizoaffective disorder
•3. Length of illness 10-15 years
•4. Currently in a clinically stable condition
•5. Current insomnia symptoms, characterised by Sleep Onset Latency (SOL) more than 30 minutes, or waking up 3 or more times per night, with an ongoing duration of the sleep problem for at least one month.
•6. Stable medication schedule and dosage for the past month
•7. English as a first language
•8. Using contraceptives (applicable to females only)
•9. Confirmation of diagnosis and suitability for the study by the potential participant’s treating psychiatrist
•10. Able to provide informed consent

•1. Diagnosis or high indication of sleep-related breathing disorder (e.g. obstructive sleep apnoea), narcolepsy, nightmare disorder, periodic limb movement syndrome, or restless legs syndrome.
•2. Suicidality.
•3. Allergy to melatonin, corn starch, gelatine
•4. BMI >35 (clinical obesity).
•5. Co-morbid significant medical conditions (e.g. seizure disorder, traumatic brain injury, dementia, autoimmune disease, liver failure, or kidney failure).
•6. Known hereditary problem of galactose intolerance, the LAPP lactase deficiency, or glucose-galactose malabsorption.
•7. Pervasive developmental disorder or mental retardation, as defined by DSM-IV or DSM-V criteria.
•8. Pregnant or breastfeeding (applicable to females only).

发起方